---
title: "Garden Biopharmaceutical: The majority of products exported to the United States are not subject to tariff increases, and price increases cannot be ruled out"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234825249.md"
description: "Yu Quanheng, the Secretary of the Board of Directors of Garden Biopharmaceutical, stated at the 2024 annual performance briefing that the majority of the company's products exported to the United States are not subject to the tariff increase effective April 2 in the U.S. The adjustment of U.S. tariff policies has limited impact on the company's export business, but the company does not rule out the possibility of price increases. The main drivers of the company's future profit growth are the production of new products and the release of existing capacity. In 2025, the company will actively promote the construction of convertible bond fundraising projects, with the main fundraising projects for biotin and VB6 expected to commence production in the second and third quarters of this year"
datetime: "2025-04-07T13:36:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234825249.md)
  - [en](https://longbridge.com/en/news/234825249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234825249.md)
generator: "portal-rs"
---

# Garden Biopharmaceutical: The majority of products exported to the United States are not subject to tariff increases, and price increases cannot be ruled out

Yu Quanheng, the Secretary of the Board of Directors of Garden Biopharmaceutical, stated at the 2024 annual performance briefing that the majority of the company's products exported to the United States are not subject to the tariff increase effective April 2 in the U.S. The adjustment of U.S. tariff policies has limited impact on the company's export business, but the company does not rule out the possibility of price increases. The main drivers of the company's future profit growth are the production of new products and the release of existing capacity. In 2025, the company will actively promote the construction of convertible bond fundraising projects, with major fundraising projects including biotin and VB6 expected to be put into production in the second and third quarters of this year

### Related Stocks

- [300401.CN](https://longbridge.com/en/quote/300401.CN.md)

## Related News & Research

- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)
- [NRED Identifies Stronger Untested IP Targets Beyond 1.67% Copper Trench Mineralization at Wilmac | NREDF Stock News](https://longbridge.com/en/news/296612079.md)
- [Jim Ratcliffe rescues vital British plastics factory from collapse](https://longbridge.com/en/news/296637993.md)
- [BYD Fang Cheng Bao launches Tai 7 DM long-range version with over 300 km EV range](https://longbridge.com/en/news/296234132.md)
- [08:31 ETTiger Group Offers Lab Equipment, Plastics Inventory and More from Grow Materials, LLC](https://longbridge.com/en/news/296491453.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**